Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.
Application: precise reprogramming of stem cells
Reprogramming stem cells into functional skeletal muscle
(9-day time course; final contraction assay by addition of acetylcholine)
Batch to batch reproducibility for applications including high throughput screening and cell therapy
Unprecedented purity results compared to current technologies.
Industrial-scale quantities and order-of-magnitude lower costs
Production takes days not months results in significant associated benefits
Current cell product offerings
Biology turns engineering
As we reach the “read/write” stage of biology, evolution is proving to be the ultimate algorithm, allowing us to increasingly program biological systems. A foundational shift in biology from being an empirical science towards becoming an engineered discipline is underway.
MD, SAB Member
Ramy is a leading immuno-oncology clinician who has helped to develop some of the breakthrough therapies in this field. Ramy has served as the Vice President of Clinical Development for Immuno-oncology at AstraZeneca, and as a member of the Bristol-Myers Squibb Immuno-oncology program. Ramy is currently the Chief Medical Officer at the Parker Institute of Cancer Immunotherapy.
MD, PhD, Founder/CEO
Mark is a stem cell biologist and neurosurgeon at the University of Cambridge. By combining synthetic and stem cell biology, his team has developed a benchmark technology for the efficient and consistent production of human cells for use in research, drug development, and cell therapy. He is the founder of Bit Bio and co-founder of the cultured meat startup Meatable.
PhD, Chief Business Officer
Paul is a serial entrepreneur and scientist with over thirty years of experience in the biotech and pharma sectors. Most recently, he was the commercial founder and President of Horizon Discovery Group, and founder of CellRx Limited, a growth factors company serving the biopharmaceutical sector. Paul holds a PhD in Biotechnology from the University of Cambridge.
PhD, Chief Scientific Advisor
Roger is a pioneer and thought leader in the field of human stem cell biology. His lab was the first to isolate pluripotent epiblast stem cells from the epiblast layer of the developing mammalian embryo. In addition, he developed one of the first cellular reprogramming protocols. Roger was co-founder of the Cambridge Stem Cell Institute. His lab is currently focused on differentiation of pluripotent stem cells, with potential applications for drug discovery, toxicity testing and cell therapies.
CFO / COO
Florian is an active entrepreneur and investor. He is the co-founder of Bit Bio. Previously, he was CFO & Head of Strategic Partnerships for Tessa Therapeutics, a clinical-stage cell therapy company. Florian is a former investment banker, a graduate of the Stanford School of Engineering, and an alumnus of Harvard Business School.
PhD, SAB Member
Marius’ seminal 2010 paper in Nature demonstrating direct conversion of fibroblasts into neurons has sparked a widespread interest in cell reprogramming. He is the co-director of the Stanford Stem Cell Institute. His lab uses cellular reprogramming to understand how neurons are induced, and how they mature and maintain their identity.
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies
Partnership will leverage Bit Bio’s unique ability to generate authentic human cells at scale WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 10,...
Published on BioSpace.
Bit Bio, a Cambridge University startup, added a number of industry luminaries to its leadership team to support its moonshot goal of developing a scalable platform technology capable of producing any human cell type.
Published on Medium.
Learn about the potential of cellular reprogramming from bit bio founder Mark Kotter.
Published on Cambridge Independent.
Bit Bio is the name of the newest cell coding company in Cambridge following a relaunch at Kettle’s Yard on Monday (October 14).
Who we are :Founded in 2016 by Dr Mark Kotter, Bit Bio (formerly Elpis Biomed) is an award-winning spinout from the University of Cambridge. By...
Published on Cambridge Independent.
The development of the Cambridge Biomedical Campus now speaks of a world-class scientific healthcare hub – and its newest arrival is Elpis BioMed, who have moved in to the Abcam building.
Published on Biotech Newswire.
Elpis was voted as the 2018 Cambridge Start-Up of the Year among a highly competitive field of life science and biotech start-ups.
Dr Jonathan Milner mentioned Elpis during his plenary lecture at the 2018 European Laboratory Research & Innovation Group (ELRIG) Drug Discovery...
Join us for a webinar with a panel of experts: Andrew Bassett PhD, Head of Research at the Wellcome Trust Sanger Institute Mark Kotter,...